Get the Stockscreener App
1,138.93
0.52%
-5.75
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,138.93, with a volume of 1.72M.
It is down -0.52% in the last 24 hours and up +20.06% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,144.68
Open:
$1152.5
24h Volume:
1.72M
Relative Volume:
0.55
Market Cap:
$1.02T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.00
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+5.56%
1M Performance:
+20.06%
6M Performance:
+14.60%
1Y Performance:
+41.07%
1-Day Range:
$1,133.53
$1,166.41
1-Week Range:
$1,101.62
$1,182.73
52-Week Range:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,139.16 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.19 | 570.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
225.70 | 398.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.29 | 295.39B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
148.25 | 284.53B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon - Reuters
AlzeCure Enters $1 Billion Collaboration and Out-Licensing Agreement with Eli Lilly - Pharmaceutical Executive
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care - Zacks Investment Research
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,300 to $1,500 - 富途牛牛
Eli Lilly (LLY) Secures FDA Approval for Ebglyss Eczema Therapy Dosing - GuruFocus
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement - Pharmaceutical Technology
Eli Lilly Obesity Drug Market Dominance 2026: Retatrutide Trial DataNews and Statistics - IndexBox
Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial - NDTV Profit
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence - BioSpace
AlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bn - European Biotechnology Magazine
Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity - BioSpace
Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw? - Insider Monkey
FDA approves Lilly’s Ebglyss for eight-week dosing regimen By Investing.com - Investing.com Canada
Eli Lilly (LLY) Receives FDA Nod for Ebglyss Maintenance Regimen - GuruFocus
Eli Lilly (LLY) Reports Positive Foundayo Weight Loss Data for Menopausal Women - Insider Monkey
Eli Lilly Wins Order Halting Alleged Trulicity Fraud - Law360
FDA approves Lilly’s Ebglyss for eight-week dosing regimen - Investing.com
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis - PR Newswire
LLY Maintained by Jefferies -- Price Target Raised to $1350 - GuruFocus
Is It Too Late To Buy The Rally In Eli Lilly Stock? - Forbes
Eli Lilly’s GLP-One Boom Is Redefining Pharma Growth - Kalkine Media
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn - Manufacturing Chemist
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - Yahoo Finance
Lilly’s “triple agonist” drug delivers striking weight loss & broad health gains in late-stage trials - Indian Pharma Post
Eli Lilly identifies new GCGR agonists - BioWorld News
Purdue Trustees Approve Elevation Of Lilly Research Center - InkFreeNews.com
AlzeCure Pharma Partners with Eli Lilly (LLY) for Alzheimer's Th - GuruFocus
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,283 to $1,500 - 富途牛牛
Lilly Deepens R&D Push in Korea with Mega-Deals - Businesskorea
Lilly's powerful new weight loss drug impresses while other experimental shots struggle - MSN
Korean biotechs sidestep Lilly-Novo showdown at ADA 2026, pitch monthly GLP-1s and next-wave obesity technologies - koreabiomed.com
Lilly’s Oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial - Indian Pharma Post
AlzeCure Pharma Soars on Major Eli Lilly Alzheimer Deal - TradingPedia
Lilly Foundation funds $5m drive to expand chronic care in Rwanda - Stock Titan
AlzeCure Pharma stock surges 301% on Eli Lilly deal By Investing.com - Investing.com Nigeria
AlzeCure Pharma stock surges 301% on Eli Lilly deal - Investing.com
Why Eli Lilly (LLY) Stock Is Up Today - Yahoo Finance
Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials - Indian Pharma Post
Eli Lilly Conspiracy Claim In Compound Drug Row Challenged - Law360
Lilly’s 30% weight loss sets high bar for obesity drug race - Indianapolis Business Journal
Why Eli Lilly Stock Climbed to a New All-Time High Today - The Motley Fool
Calmer waters for FDA; Servier , Lilly deals — a BioCentury podcast - biocentury.com
Sizing up Lilly’s dealmaking spree - biocentury.com
Pharos iBio Joins Eli Lilly’s Global AI Drug Discovery Ecosystem - 아시아경제
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy? - The Motley Fool
The Investment Case for Eli Lilly and Co (LLY): How Financial Gr - GuruFocus
Top 20 by Trading Volume | Chip stocks rebound across the board, with Intel surging over 11% after securing a major order from Google for 3 million TPUs, Marvell rising nearly 10%, and AMD gaining more than 5%; Eli Lilly and Co. pioneers a new frontier in - 富途牛牛
Eli Lilly and Co Options Spot-On: On June 8th, 73,672 Contracts Were Traded, With 388.59K Open Interest - Moomoo
Eli Lilly (LLY) Shares Rise After Positive Phase 3 Diabetes Drug Data - GuruFocus
Eli Lilly (LLY) Reports Promising Results from Phase 3 Trials of Foundayo - GuruFocus
Lilly's oral GLP-1 Foundayo delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials - Investing News Network
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):